Navigation Links
Cynvenio Releases ClearID® Lung Cancer: a Highly-Targeted Genomic Blood Test for Lung and Thoracic Cancer Patients
Date:5/16/2017

Cynvenio Biosystems, Inc. a leader in personalized medicine technology and cancer diagnostics, has released its ClearID Lung Cancer blood test. Leveraging a highly-sensitive next-generation sequencing panel of 11 genes known to be altered in lung cancer, this new test is designed to quickly and accurately identify tumor-related genetic mutations that can be treated with targeted therapies.

ClearID Lung Cancer uses Cynvenio’s LiquidBiopsy® approach to identify circulating tumor DNA burden and detects somatic mutations as low as 0.13% with an accuracy of 99.76%, and a sensitivity of 95.9%. The test can be used at initial diagnosis to support treatment stratification and identification of targeted therapies. During treatment, it can be used to detect emergent genetic mutations associated with resistance to therapy and identify alternate therapeutic options.

The test results are available within 5-7 days and summarized in a report containing clinical interpretations of the identified biomarkers and variants, their association with drugs, related clinical trials, and experimental therapies to support treatment strategies.

“ClearID Lung Cancer provides physicians and their patients with a customized lung cancer panel that is focused on actionable mutations," said Dr. Paul Y. Song, Cynvenio’s Chief Medical Officer. "With a rapid turnaround time, the test enables quicker response times and more individualized and effective treatment.”

ClearID Lung Cancer can be used to complement conventional tissue biopsy. Requiring only a standard blood draw, ClearID is easier on the patient and can be repeated frequently to monitor changes in tumor status over time. ClearID is particularly useful when there is difficulty obtaining tissue biopsy material, or when it is not practical or advisable to do so for clinical reasons.

About Cynvenio Biosystems, Inc.

Cynvenio’s liquid biopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients.  Among the company’s breakthroughs is its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third party diagnostic labs. Cynvenio is based in Westlake Village, California. For more information, please visit http://www.cynvenio.comhttp://www.clearidmonitoring.com and http://www.liquidbiopsy.com.

LiquidBiopsy® and ClearID® are registered trademarks of Cynvenio Biosystems, Inc.

Read the full story at http://www.prweb.com/releases/2017/05/prweb14339502.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Cynvenio and TME Research Announce Neoadjuvant Breast Cancer Monitoring Study (NEAT)
2. Cynvenio Releases Two New High Recovery LiquidBiopsy® CTC Capture Kits at 2017 AACR Annual Meeting in Washington, DC.
3. Cynvenio Biosystems Announces Expansion of Payer Network with Addition of Blue Cross Blue Shield of Illinois
4. Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test
5. Cynvenio and CollabRx Announce Partnership for Cancer Molecular Diagnostics
6. Cynvenio Biosystems Receives CLIA Certification for its Genomic Sequencing Laboratory
7. Cynvenio Biosystems to Present Clinical Data on Mutational Analysis of LiquidBiopsy® Tumor Samples at the 2013 ASCO Annual Meeting
8. METTLER TOLEDO Releases Conductivity Converter App
9. TOMA Biosciences Releases the COMPASS Tumor Profiling System
10. LabKey Releases Software Solution for Accelerating Large Molecule Development
11. AxioMed Releases Video Demonstrating Viscoelastic Properties of its Freedom Disc Replacement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published in ... and fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched ... , After comparing the results from the fresh and frozen transfer cohorts, the ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and ... rebranding initiative announced today. The bold new look is part of a transformation ... moves into a significant growth period. , It will also expand its service offering ...
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks ... Strategy, will speak at the TMA 2017 Annual Meeting , October ... trends in the residential home security market and how smart safety and ... Parks ... "The residential ...
Breaking Biology Technology:
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/23/2017)... -- The report "Gesture Recognition and Touchless Sensing Market by Technology ... Forecast to 2022", published by MarketsandMarkets, the market is expected to be worth ... and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):